Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
SGLT2 inhibitor |
| gptkbp:approvalYear |
2014
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
A10BK01
|
| gptkbp:brand |
gptkb:Forxiga
gptkb:Farxiga |
| gptkbp:CASNumber |
461432-26-8
|
| gptkbp:contraindication |
gptkb:type_1_diabetes_mellitus
severe renal impairment |
| gptkbp:developedBy |
gptkb:AstraZeneca
|
| gptkbp:discoveredBy |
gptkb:Bristol-Myers_Squibb
|
| gptkbp:eliminationHalfLife |
12.9 hours
|
| gptkbp:hasMolecularFormula |
C21H25ClO6
|
| https://www.w3.org/2000/01/rdf-schema#label |
Dapagliflozin
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits sodium-glucose co-transporter 2
|
| gptkbp:proteinBinding |
91%
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
urinary tract infection
dehydration genital infection ketoacidosis |
| gptkbp:usedFor |
gptkb:type_2_diabetes_mellitus
heart failure chronic kidney disease |
| gptkbp:bfsParent |
gptkb:Zentiva
|
| gptkbp:bfsLayer |
7
|